Nanopatterned Microfluidic Chip Detects Cancer Markers
|
By LabMedica International staff writers Posted on 13 Mar 2019 |

Image: The three-dimensional (3D) herringbone nanopatterned microfluidic chip that detects cancer faster (Photo courtesy of the University of Kansas).
The performance of current microfluidic methods for exosome detection is constrained by boundary conditions, as well as fundamental limits to microscale mass transfer and interfacial exosome binding.
Some types of cancer, such as ovarian cancer, tend to remain undetected until they are too advanced for treatment to be effective. Now, an innovative tool may be able to detect cancer easily, quickly, and in minuscule amounts of blood. A device, which is called a "3D-nanopatterned microfluidic chip," could successfully detect cancer markers in the tiniest drop of blood or in a component of the blood called plasma.
Biochemists at the University of Kansas (Lawrence, KS, USA) and their colleagues have shown that a microfluidic chip designed with self-assembled three-dimensional herringbone nanopatterns can detect low levels of tumor-associated exosomes in plasma (10 exosomes μL−1, or approximately 200 vesicles per 20 μL of spiked sample) that would otherwise be undetectable by standard microfluidic systems for biosensing. The nanopatterns promote microscale mass transfer, increase surface area and probe density to enhance the efficiency and speed of exosome binding, and permit drainage of the boundary fluid to reduce near-surface hydrodynamic resistance, thus promoting particle–surface interactions for exosome binding.
The scientists used the device for the detection, in 2 μL plasma samples from 20 ovarian cancer patients and 10 age-matched controls, of exosome subpopulations expressing CD24, epithelial cell adhesion molecule and folate receptor alpha proteins. They suggest exosomal folate receptor alpha as a potential biomarker for early detection and progression monitoring of ovarian cancer. The nanolithography-free nanopatterned device should facilitate the use of liquid biopsies for cancer diagnosis.
Yong Zeng, PhD, an associate professor of chemistry and the senior author of the study, said, “Historically, people thought exosomes were like 'trash bags' that cells could use to dump unwanted cellular contents. But, in the past decade scientists realized they were quite useful for sending messages to recipient cells and communicating molecular information important in many biological functions. Basically, tumors send out exosomes packaging active molecules that mirror the biological features of the parental cells. While all cells produce exosomes, tumor cells are really active compared to normal cells.” The study was published on February 25, 2019, in the journal Nature Biomedical Engineering.
Related Links:
University of Kansas
Some types of cancer, such as ovarian cancer, tend to remain undetected until they are too advanced for treatment to be effective. Now, an innovative tool may be able to detect cancer easily, quickly, and in minuscule amounts of blood. A device, which is called a "3D-nanopatterned microfluidic chip," could successfully detect cancer markers in the tiniest drop of blood or in a component of the blood called plasma.
Biochemists at the University of Kansas (Lawrence, KS, USA) and their colleagues have shown that a microfluidic chip designed with self-assembled three-dimensional herringbone nanopatterns can detect low levels of tumor-associated exosomes in plasma (10 exosomes μL−1, or approximately 200 vesicles per 20 μL of spiked sample) that would otherwise be undetectable by standard microfluidic systems for biosensing. The nanopatterns promote microscale mass transfer, increase surface area and probe density to enhance the efficiency and speed of exosome binding, and permit drainage of the boundary fluid to reduce near-surface hydrodynamic resistance, thus promoting particle–surface interactions for exosome binding.
The scientists used the device for the detection, in 2 μL plasma samples from 20 ovarian cancer patients and 10 age-matched controls, of exosome subpopulations expressing CD24, epithelial cell adhesion molecule and folate receptor alpha proteins. They suggest exosomal folate receptor alpha as a potential biomarker for early detection and progression monitoring of ovarian cancer. The nanolithography-free nanopatterned device should facilitate the use of liquid biopsies for cancer diagnosis.
Yong Zeng, PhD, an associate professor of chemistry and the senior author of the study, said, “Historically, people thought exosomes were like 'trash bags' that cells could use to dump unwanted cellular contents. But, in the past decade scientists realized they were quite useful for sending messages to recipient cells and communicating molecular information important in many biological functions. Basically, tumors send out exosomes packaging active molecules that mirror the biological features of the parental cells. While all cells produce exosomes, tumor cells are really active compared to normal cells.” The study was published on February 25, 2019, in the journal Nature Biomedical Engineering.
Related Links:
University of Kansas
Latest Clinical Chem. News
- Combined Blood and Imaging Data Help Identify More Lung Cancer Cases
- Blood Protein Panel Detects ALS with High Accuracy
- Single-Vesicle Analysis Reveals Tissue-Associated Inflammatory Signatures
- Plasma Proteomic Test Detects Immunotherapy Resistance Before Imaging in Lung Cancer
- Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging
- Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring
- Blood-Based Score May Support Targeted Interventions for Healthier Aging
- Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury
- Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
- Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
- Common Kidney Function Tests May Miss CKD in Cancer Patients
- Point-of-Care Blood Biomarker Test Detects Brain Injury Missed by CT
- Daily Blood Testing May Help Guide Earlier Antibiotic Stopping in Sepsis
- Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis
- Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
- Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
Channels
Molecular Diagnostics
view channel
Circulating Tumor DNA Test Identifies Complete Responders in Metastatic Cancer Immunotherapy
Immune checkpoint inhibitors have transformed treatment for many metastatic cancers, with some patients achieving durable disease control. However, clinicians remain uncertain about how long therapy should... Read more
New Research Examines Hi-C Sequencing Across Solid Tumors and Lymphoma
Arima Genomics (Carlsbad, CA, USA) will present new research highlighting the expanding clinical applications of its Aventa FusionPlus and Aventa Lymphoma tests at the Association for Molecular Pathology... Read moreHematology
view channel
New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients
Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more
Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers
Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways
Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more
Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel
Respiratory infections often cause overlapping viral and bacterial symptoms, making diagnosis more difficult during peak respiratory seasons. This uncertainty can be especially important for high-risk... Read more
Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
T-follicular helper cell lymphoma (TFHL) is a subtype of peripheral T-cell lymphoma associated with poor prognosis and limited treatment options after relapse. Its molecular abnormalities include frequent... Read more
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read moreMicrobiology
view channel
Gastrointestinal Flex Assay Receives EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business
Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more
Agilent Completes Acquisition of Digital Pathology Platform Developer Proscia
Agilent Technologies has completed its acquisition of Proscia, a provider of digital pathology software for clinical and life sciences applications. The transaction involved a cash payment of USD 240 million... Read more
New Diagnostics Company Onvaro Formed to Expand Decentralized Testing
Sapphiros, a diagnostics platform backed by investment funds managed by KKR, and binx health, a point-of-care diagnostics company backed by Hildred, have combined to form Onvaro. The new diagnostics company... Read more







